{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:25:44Z","timestamp":1793226344232,"version":"4.5.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI148055"],"award-info":[{"award-number":["U01 AI148055"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI120176"],"award-info":[{"award-number":["UM1 AI120176"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI149665"],"award-info":[{"award-number":["AI149665"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R24 AI118397)"],"award-info":[{"award-number":["R24 AI118397)"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization\/","doi-asserted-by":"crossref","award":["2020-39-GLAD)"],"award-info":[{"award-number":["2020-39-GLAD)"]}],"id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>High-extraction protease inhibitors (eg, for human immunodeficiency virus and severe acute respiratory syndrome coronavirus 2) typically require ritonavir to enhance bioavailability by overcoming first-pass metabolism. However, in the long-acting subcutaneous injectable dosage form TLC-ART 101, lopinavir persisted in plasma for 57 days, while ritonavir was detectable for only 3\u20137 days. The remarkable duration of lopinavir suggests that ritonavir may be unnecessary in long-acting injectable products, potentially reducing side effects and drug\u2013drug interactions.<\/jats:p>","DOI":"10.1093\/infdis\/jiaf319","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T13:07:56Z","timestamp":1751029676000},"page":"607-611","source":"Crossref","is-referenced-by-count":3,"title":["Long-acting Injectable Containing Lopinavir Eliminates Reliance on Ritonavir Pharmacokinetic Enhancement"],"prefix":"10.1093","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4498-7823","authenticated-orcid":false,"given":"Simone","family":"Perazzolo","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4495-5349","authenticated-orcid":false,"given":"Charles W","family":"Flexner","sequence":"additional","affiliation":[{"name":"Divisions of Clinical Pharmacology and Infectious Diseases, Departments of Medicine, Pharmacology and Molecular Sciences, and International Health, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2014-3100","authenticated-orcid":false,"given":"Zachary R","family":"Stephen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P","family":"Acosta","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, School of Medicine, University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6167-1447","authenticated-orcid":false,"given":"Rachel A","family":"Bender Ignacio","sequence":"additional","affiliation":[{"name":"Division of Allergy and Infectious Diseases, School of Medicine, University of Washington , Seattle, Washington ,","place":["USA"]},{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5960-4288","authenticated-orcid":false,"given":"Rodney J Y","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, University of Washington , Seattle, Washington ,","place":["USA"]},{"name":"Department of Bioengineering, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"2025092306175960500_jiaf319-B1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0169-409X(97)00039-2","article-title":"Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction","volume":"27","author":"Thummel","year":"1997","journal-title":"Adv Drug Deliv Rev"},{"key":"2025092306175960500_jiaf319-B2","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.110.037523","article-title":"Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir","volume":"39","author":"Kirby","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"2025092306175960500_jiaf319-B3","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.xphs.2020.11.019","article-title":"Systems and clinical pharmacology of COVID-19 therapeutic candidates: a clinical and translational medicine perspective","volume":"110","author":"Perazzolo","year":"2021","journal-title":"J Pharm Sci"},{"key":"2025092306175960500_jiaf319-B4","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1128\/AAC.42.12.3218","article-title":"ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease","volume":"42","author":"Sham","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092306175960500_jiaf319-B5","author":"Bender-Ignacio"},{"key":"2025092306175960500_jiaf319-B6","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1023\/B:PHAM.0000041457.64638.8d","article-title":"Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans","volume":"21","author":"Kumar","year":"2004","journal-title":"Pharm Res"},{"key":"2025092306175960500_jiaf319-B7","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the management of drug\u2013drug interactions between the COVID-19 antiviral nirmatrelvir\/ritonavir (Paxlovid) and comedications","volume":"112","author":"Marzolini","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2025092306175960500_jiaf319-B8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cpt.1284","article-title":"Modern human immunodeficiency virus therapy: progress and prospects","volume":"105","author":"Flexner","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2025092306175960500_jiaf319-B9","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.xphs.2020.01.016","article-title":"Integration of computational and experimental approaches to elucidate mechanisms of first-pass lymphatic drug sequestration and long-acting pharmacokinetics of the injectable triple-HIV drug combination TLC-ART 101","volume":"109","author":"Perazzolo","year":"2020","journal-title":"J Pharm Sci"},{"key":"2025092306175960500_jiaf319-B10","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4155\/tde.11.19","article-title":"Flip-flop pharmacokinetics\u2014delivering a reversal of disposition: challenges and opportunities during drug development","volume":"2","author":"Y\u00e1\u00f1ez","year":"2011","journal-title":"Ther Deliv"},{"key":"2025092306175960500_jiaf319-B11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.addr.2016.02.003","article-title":"Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: insights for applications in HIV therapy","volume":"103","author":"Owen","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"2025092306175960500_jiaf319-B12","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.xphs.2024.02.018","article-title":"Physiologically based pharmacokinetic model validated to enable predictions of multiple drugs in a long-acting drug-combination nano-particles (DcNP): confirmation with 3 HIV drugs, lopinavir, ritonavir, and tenofovir in DcNP products","volume":"113","author":"Perazzolo","year":"2024","journal-title":"J Pharm Sci"},{"key":"2025092306175960500_jiaf319-B13","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1097\/QAD.0000000000001969","article-title":"Extended cell and plasma drug levels after one dose of a 3-in-1 nanosuspension containing lopinavir, efavirenz, and tenofovir in non-human primates","volume":"32","author":"Koehn","year":"2018","journal-title":"AIDS"},{"key":"2025092306175960500_jiaf319-B14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/B978-0-12-819869-8.00035-5","volume-title":"Atkinson\u2019s principles of clinical pharmacology","author":"Foster","year":"2022","edition":"4th ed"},{"key":"2025092306175960500_jiaf319-B15","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0009-9236(03)00006-7","article-title":"Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors","volume":"73","author":"Washington","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"2025092306175960500_jiaf319-B16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.xphs.2021.10.009","article-title":"Physiologically based pharmacokinetic modeling of 3 HIV drugs in combination and the role of lymphatic system after subcutaneous dosing. Part 2: model for the drug-combination nanoparticles","volume":"111","author":"Perazzolo","year":"2022","journal-title":"J Pharm Sci"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf319\/63523329\/jiaf319.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/3\/607\/63523329\/jiaf319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/3\/607\/63523329\/jiaf319.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T10:25:47Z","timestamp":1758623147000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/232\/3\/607\/8168820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6,24]]},"published-print":{"date-parts":[[2025,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf319","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,15]]},"published":{"date-parts":[[2025,6,24]]}}}